Roman Gulati

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. pmc The impact of PLCO control arm contamination on perceived PSA screening efficacy
    Roman Gulati
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    Cancer Causes Control 23:827-35. 2012
  2. pmc What if i don't treat my PSA-detected prostate cancer? Answers from three natural history models
    Roman Gulati
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 20:740-50. 2011
  3. pmc Calibrating disease progression models using population data: a critical precursor to policy development in cancer control
    Roman Gulati
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biostatistics 11:707-19. 2010
  4. pmc The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines
    Ruth Etzioni
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Cancer 118:5955-63. 2012
  5. pmc Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer
    Evan Y Yu
    University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Clin Oncol 30:1864-70. 2012
  6. pmc Individualized estimates of overdiagnosis in screen-detected prostate cancer
    Roman Gulati
    Affiliations of authors Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA RG, JK, RE Department of Biostatistics LYTI and Department of Urology JLG, University of Washington, Seattle, WA
    J Natl Cancer Inst 106:djt367. 2014
  7. pmc Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms
    Roman Gulati
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M2 B230, PO Box 19024, Seattle, WA 98109 1024, USA
    Ann Intern Med 158:145-53. 2013
  8. pmc Prostate cancer mortality following active surveillance versus immediate radical prostatectomy
    Jing Xia
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, WA, USA
    Clin Cancer Res 18:5471-8. 2012
  9. pmc Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence
    Ruth Etzioni
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Med Care 51:304-6. 2013
  10. pmc Quantifying the role of PSA screening in the US prostate cancer mortality decline
    Ruth Etzioni
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer Causes Control 19:175-81. 2008

Detail Information

Publications24

  1. pmc The impact of PLCO control arm contamination on perceived PSA screening efficacy
    Roman Gulati
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    Cancer Causes Control 23:827-35. 2012
    ..To quantify the extent to which a clinically significant prostate cancer mortality reduction due to screening could have been masked by control arm screening (contamination) in the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial...
  2. pmc What if i don't treat my PSA-detected prostate cancer? Answers from three natural history models
    Roman Gulati
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 20:740-50. 2011
    ....
  3. pmc Calibrating disease progression models using population data: a critical precursor to policy development in cancer control
    Roman Gulati
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biostatistics 11:707-19. 2010
    ..The model produces representative outcomes for selected PSA screening policies and is shown to be useful for informing the development of sound cancer control policy...
  4. pmc The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines
    Ruth Etzioni
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Cancer 118:5955-63. 2012
    ..Prostate cancer mortality rates in the United States declined by >40% between 1991 and 2005. The impact of changes in primary treatment and adjuvant and neoadjuvant hormone therapy on this decline is unknown...
  5. pmc Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer
    Evan Y Yu
    University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Clin Oncol 30:1864-70. 2012
    ..To investigate changes in bone mineral density (BMD) and fracture risk in men who received intermittent androgen deprivation (IAD) for nonmetastatic, hormone-sensitive prostate cancer...
  6. pmc Individualized estimates of overdiagnosis in screen-detected prostate cancer
    Roman Gulati
    Affiliations of authors Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA RG, JK, RE Department of Biostatistics LYTI and Department of Urology JLG, University of Washington, Seattle, WA
    J Natl Cancer Inst 106:djt367. 2014
    ..The purpose of this study is to use age, Gleason score, and prostate-specific antigen (PSA) level to help inform patients with screen-detected prostate cancers about the chances their cancers were overdiagnosed...
  7. pmc Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms
    Roman Gulati
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M2 B230, PO Box 19024, Seattle, WA 98109 1024, USA
    Ann Intern Med 158:145-53. 2013
    ..The U.S. Preventive Services Task Force recently concluded that the harms of existing prostate-specific antigen (PSA) screening strategies outweigh the benefits...
  8. pmc Prostate cancer mortality following active surveillance versus immediate radical prostatectomy
    Jing Xia
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, WA, USA
    Clin Cancer Res 18:5471-8. 2012
    ..The purpose of this study is to project prostate cancer mortality under active surveillance followed by radical prostatectomy versus under immediate radical prostatectomy...
  9. pmc Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence
    Ruth Etzioni
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Med Care 51:304-6. 2013
    ..Although we acknowledge the centrality of screening trials in the policy process, we maintain that modeling constitutes a powerful tool for screening trial interpretation and screening policy development...
  10. pmc Quantifying the role of PSA screening in the US prostate cancer mortality decline
    Ruth Etzioni
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer Causes Control 19:175-81. 2008
    ..To quantify the plausible contribution of prostate-specific antigen (PSA) screening to the nearly 30% decline in the US prostate cancer mortality rate observed during the 1990s...
  11. doi request reprint Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach
    Ruth Etzioni
    Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Med Decis Making 28:323-31. 2008
    ..The objective was to quantify this link between PSA screening and the decline in distant stage incidence...
  12. pmc Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial
    Jing Xia
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 105:546-50. 2013
    ..1% to 6.5%) after 12 years. It is not known whether a higher frequency of screen detection in PIVOT explains the lower AMD...
  13. pmc Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening
    Ruth Etzioni
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Med Care 51:295-300. 2013
    ....
  14. pmc Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia?
    Jeannette M Schenk
    Fred Hutchinson Cancer Research Center, Cancer Prevention Program, Seattle, WA 98109 1024, USA
    Am J Epidemiol 178:741-51. 2013
    ..61, 0.65); however there were no cut points at which sensitivity and specificity were both above 75%. We concluded that moderate elevations in PSA, IPSS, or their rates of change should not be used as surrogate measures of incident BPH. ..
  15. pmc Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening
    Ruth Etzioni
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Ann Intern Med 158:831-8. 2013
    ....
  16. pmc Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation
    Evan Y Yu
    Department of Medicine, Division of Oncology, University of Washington, 825 Eastlake Ave E, Seattle, WA 98109, USA
    J Clin Oncol 28:2668-73. 2010
    ....
  17. pmc Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates
    Roman Gulati
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Clin Epidemiol 64:1412-7. 2011
    ..To project long-term estimates of the number needed to screen (NNS) and the additional number needed to treat (NNT) to prevent one prostate cancer death with prostate-specific antigen (PSA) screening in Europe and in the United States...
  18. pmc Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States
    Megan Dann Fesinmeyer
    Fred Hutchinson Cancer Research Center, Department of Veterans Affairs Puget Sound Health Care System, Fairview Avenue North, M2 B230, PO Box 19024, Seattle WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 18:808-15. 2009
    ..0% (under different survival for obese and nonobese cases) in 2002. We conclude that increasing obesity prevalence since 1980 has partially obscured declines in prostate cancer mortality...
  19. pmc The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells
    Colm Morrissey
    Department of Urology, University of Washington, Seattle, Washington 98195, USA
    Prostate 70:412-24. 2010
    ..Tumor cells replace bone marrow and can elicit an osteoblastic, osteolytic, or mixed bone response. Our objective was to elucidate the mechanisms and key factors involved in promoting osteoclastogenesis in PCa bone metastasis...
  20. pmc Single cell transcriptomic analysis of prostate cancer cells
    Christopher J Welty
    Department of Urology, University of Washington, Seattle, WA, USA
    BMC Mol Biol 14:6. 2013
    ..A high stringency threshold, a mean Alexa Fluor® 3 signal intensity above 300, was used for gene detection. Relative expression levels were validated for select genes using real-time PCR (RT-qPCR)...
  21. ncbi request reprint Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends
    Donatello Telesca
    Department of Statistics, University of Washington, Seattle, WA 98195 4322, USA
    Biometrics 64:10-9. 2008
    ....
  22. doi request reprint Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma
    Dan Lewinshtein
    Virginia Mason Medical Center Urology and Renal Transplantation, Fred Hutchinson Cancer Research Center Human Biology, Seattle, WA, USA
    BJU Int 109:706-12. 2012
    ..To quantify the risk of specific second primary malignancies (SPMs) associated with radiation exposure in these patients...
  23. pmc Associations of very high intakes of eicosapentaenoic and docosahexaenoic acids with biomarkers of chronic disease risk among Yup'ik Eskimos
    Zeina Makhoul
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Am J Clin Nutr 91:777-85. 2010
    ..Few studies have examined the associations of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) with biomarkers of chronic disease risk in populations with high intakes...
  24. pmc Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells
    Colm Morrissey
    Genitourinary Cancer Research Laboratory, Department of Urology, University of Washington, Seattle, WA 98195, USA
    Anticancer Drugs 21:423-32. 2010
    ..This study shows the potential use of artemisinin derivatives as therapeutic candidates for PCa and warrants the initiation of preclinical studies...